← All indications
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Subtype terms (4)
More specific conditions that are subtypes of Pancreatic Neoplasms in the MeSH hierarchy.
- Adenoma, Islet Cell
21 drugs (20 approved, 1 experimental)
- Carcinoma, Islet Cell
28 drugs (22 approved, 6 experimental)
- Carcinoma, Pancreatic Ductal
50 drugs (32 approved, 18 experimental)
- Pancreatic Intraductal Neoplasms
9 drugs (7 approved, 2 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (66)
- pancrelipase
- desflurane
- insulin human
- potassium chloride
- urea
- s-1
- sodium chloride
- dalteparin
- tinzaparin
- magnesium
- glimepiride
- hydroxyethyl starch
- fish oil
- nicotine
- etomidate
- sodium acetate
- vitamin c
- tegafur
- albumin (Human)
- fluorouracil
- bupropion
- everolimus
- capecitabine
- pembrolizumab
- dexamethasone
- dronabinol
- gimeracil
- ethanol
- somatostatin
- gelatin
- +36 more
Phase 3 trials (114)
- mrtx1719
- pemetrexed
- rubitecan
- cabozantinib
- Fosgemcitabine
- lutetium dotatate lu-177
- bevacizumab
- zarnestra
- asparaginase
- rmc-6236
- pertuzumab
- levocarnitine
- napabucasin
- interleukin-10
- folic acid
- tazobactam
- 68ga-dotanoc
- anlotinib
- ganitumab
- esmolol
- exatecan
- gastrin 17 vaccine
- nis793
- secretin human
- piperacillin
- atezolizumab
- epirubicin
- folfirinox
- lanreotide
- levoleucovorin
- +84 more
Phase 2 trials (679)
Phase 1 trials (434)
- mnpr-101-dfo*-89zr
- bbi-355
- u87 car-t
- cbt-101
- tqb2858
- monomethyl auristatin e
- cantuzumab ravtansine
- sea-cd40
- arq 761
- dsp-7888
- ly4101174
- tbi-1401
- cobicistat
- cht102
- birabresib
- umbilical cord blood derived mak immune cells
- 111in-ipn01087
- ly3962673
- pegylated arginine deiminase
- rv-nyeso tcr pbmc
- gem3psca
- cp-870893
- amt-151
- gv20-0251
- ciforadenant
- 18f substance p
- ly3300054
- cl-nk-001
- np-g2-044
- abo2102
- +404 more
Other trials (62)
- car-cld18 t cells
- motexafin lutetium
- water
- canagliflozin
- gum
- piflufolastat
- bazedoxifene
- sevoflurane
- ms-20
- varenicline
- [68ga]ga-nota-wwh347
- perflutren protein-type a microspheres
- graviola
- [18f]f-resca-rb14
- agen2034
- cu 64 m5a
- sodium phosphate
- acetic acid
- rbs2418
- [18f]f-resca-t4
- zinc
- xh001
- autologous islet
- bcma-pd1-cart cell
- 68ga-nota-gpa33
- allogeneic adipose derived mesenchymal stem cell
- autologous dendritic cells electroporated with wt1 mrna
- synthetic secretin
- sulfur hexafluoride lipid-type a microspheres
- olanzapine
- +32 more
Organizations
Organization Involved with Phase 4 Indications (26)
- Harvard University
- Hasselt University
- Fudan University
- Temple University
- Georgetown University
- University of Texas at Houston
- Cantonal Hospital of St. Gallen
- Region Skane
- Cantonal Hospital Winterthur
- Uppsala University
- AbbVie
- Triemli Hospital
- Seoul National University
- Sir Run Run Shaw Hospital
- National Cancer Institute (NCI)
- Zhejiang University
- Eisai
- Indiana University
- University of Helsinki
- Peking University
- RenovoRx
- People's Liberation Army of China
- Institut Hospital del Mar d'Investigacions Mèdiques
- Roche
- University of Zurich
- University of Ulsan
Organization Involved with Phase 3 Indications (201)
- Northwestern University
- ARMO BioSciences
- NewLink Genetics Inc
- Hengrui Therapeutics, Inc.
- Shire
- University Hospital of North Norway
- Eastern Cooperative Oncology Group
- Wellstat Therapeutics
- Jeju National University
- AstraZeneca
- NRG Oncology
- Pancreatic Cancer Action Network
- Friedrich Schiller University
- Aix-University of Marseille
- CancerCare Manitoba
- NanoCarrier Co., Ltd.
- Advocate Illinois Masonic Medical Center
- University of Ottawa
- The Cleveland Clinic
- University of Bergen
- AIO-Studien-gGmbH
- Erasmus University Rotterdam
- Jiao Tong University
- Par Pharmaceuticals
- Yeshiva University
- Daiichi Sankyo
- University of Mannheim
- University of Verona
- University of Rostock
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- +171 more
Organization Involved with Phase 2 Indications (410)
- University of California, Los Angeles
- Garden State Cancer Center
- Rgene Corporation
- Ascentage Pharma Group Inc.
- Hellenic Oncology Research Group
- Golden Biotechnology Corp.
- Oklahoma Oncology
- Central European Society for Anticancer Drug Research (CESAR)
- Minneamrita Therapeutics LLC
- Green Cross Corporation
- Trinity College Dublin
- University of Manchester
- Japan Adjuvant Study Group of Pancreatic Cancer
- Reata Pharmaceuticals, Inc.
- Nagoya University
- University of Miami
- Universidad Complutense de Madrid
- Susan L Bader Foundation of Hope
- Boehringer Ingelheim
- Universidad Autonoma de Barcelona
- University of Grenoble
- Brown University
- Mereo BioPharma
- Vall d'Hebron Institute of Research, Galatea Clinic
- Philipps University of Marburg
- Piramal
- HonorHealth Research Institute
- Soonchunhyang University
- Dong-A University
- BerGenBio ASA
- +380 more
Organization Involved with Phase 1 Indications (104)
- XBiotech, Inc.
- DrugCendR Inc.
- US Oncology
- MannKind Corp
- IRCCS CANDIOLO
- Reliable Cancer Therapies
- SciQuus Oncology
- Lotte & John Hecht Memorial Foundation
- Amarex Clinical Research
- Syntrix Biosystems, Inc.
- Wyeth
- National Center for Complementary and Integrative Health (NCCIH)
- Cha Medical University
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Biosplice Therapeutics
- Triphase Research and Development Corporation
- inVentiv
- SN BioScience
- St. Luke's-Roosevelt Hospital Center
- University of Cambridge
- Medivation
- Orlando Health
- Shandong University
- Dynavax Technologies Corporation
- Immunogen
- Boston University
- Inspirna, Inc.
- Envita Medical Centers
- North Shore Hospital, New Zealand
- University of Colorado, Denver
- +74 more
Organization Involved with Other Experimental Indications (24)
- National University of Ireland
- University of Montreal
- University of Nantes
- Shenzhen BinDeBio Ltd.
- National Center for Research Resources (NCRR)
- IlDong Pharmaceutical Co Ltd
- Aveni Foundation
- Hope Biosciences
- Olympus
- University of Gothenburg
- Centro Integral Oncológica Clara Campal
- Argos Therapeutics
- University of Vermont
- Government of Korea
- Guangzhou Medical University
- Herbert Irving Comprehensive Cancer Center
- Jilin University
- Rockefeller University
- Dutch Cancer Society
- ImaginAb, Inc.
- Sarcoma Oncology Research Center, LLC
- University of Modena and Reggio Emilia
- Microbio Co Ltd
- myTomorrows